POLD1 Recombinant Monoclonal Antibody

說明書

中文名稱：

POLD1 Recombinant Monoclonal Antibody
貨號：

CSB-RA207245A0HU
規格：

￥1320
圖片：
Western Blot
Positive WB detected in: A431 whole cell lysate(30μg), K562 whole cell lysate(30μg), HL-60 whole cell lysate(30μg), Jurkat whole cell lysate(30μg), THP-1 whole cell lysate(30μg)
All lanes: POLD1 antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/40000 dilution
Predicted band size: 124 kDa
Observed band size: 132 kDa
Exposure time：20s

IHC image of CSB-RA207245A0HU diluted at 1:100 and staining in paraffin-embedded human gastric cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.

IHC image of CSB-RA207245A0HU diluted at 1:100 and staining in paraffin-embedded human small intestine tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.

Overlay Peak curve showing jurkat cells stained with CSB-RA207245A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for?10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P28340
基因名：

POLD1
別名：

DNA polymerase delta catalytic subunit (EC 2.7.7.7) (EC 3.1.11.-) (DNA polymerase subunit delta p125), POLD1, POLD
反應種屬：

Human
免疫原：

A synthesized peptide from human POLD1 protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

24B10
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC, FC

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:50-1:200
FC	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Flow cytometry (FC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

As the catalytic component of the trimeric (Pol-delta3 complex) and tetrameric DNA polymerase delta complexes (Pol-delta4 complex), plays a crucial role in high fidelity genome replication, including in lagging strand synthesis, and repair. Exhibits both DNA polymerase and 3'- to 5'-exonuclease activities. Requires the presence of accessory proteins POLD2, POLD3 and POLD4 for full activity. Depending upon the absence (Pol-delta3) or the presence of POLD4 (Pol-delta4), displays differences in catalytic activity. Most notably, expresses higher proofreading activity in the context of Pol-delta3 compared with that of Pol-delta4. Although both Pol-delta3 and Pol-delta4 process Okazaki fragments in vitro, Pol-delta3 may be better suited to fulfill this task, exhibiting near-absence of strand displacement activity compared to Pol-delta4 and stalling on encounter with the 5'-blocking oligonucleotides. Pol-delta3 idling process may avoid the formation of a gap, while maintaining a nick that can be readily ligated. Along with DNA polymerase kappa, DNA polymerase delta carries out approximately half of nucleotide excision repair (NER) synthesis following UV irradiation. Under conditions of DNA replication stress, in the presence of POLD3 and POLD4, may catalyze the repair of broken replication forks through break-induced replication (BIR). Involved in the translesion synthesis (TLS) of templates carrying O6-methylguanine, 8oxoG or abasic sites.
基因功能參考文獻：
1. data suggest that SIRT1 is an oncogenic factor in breast cancer cells and can be involved in the progression of breast cancer by inhibiting p53 and activating POLD1 PMID: 29807012
2. findings demonstrate a key role of POLD1 and POLD3 in genome stability and S-phase progression revealing RNA-DNA hybrids-dependent effects for POLD3 that might be partly due to its Pol zeta interaction. PMID: 27974823
3. Mutation in DNA Polymerase III gene is associated with MMR deficiency in cancer. PMID: 28512192
4. POLD1 played important roles in regulating cell cycle- and DNA replication-related pathways. E2F could upregulate the expression levels of POLD1 by deregulating the methylations of their promoters to promote the relapse of Acute Lymphoblastic Leukemia . PMID: 29768346
5. DNA polymerase delta catalytic subunit controls noncentrosomal gammaTuRC activity and regulates the organization of Golgi-derived microtubules. PMID: 28916777
6. POLH & POLK are both able to exchange with PolD1 stalled at repetitive CFS (common fragile sites) sequences. POLD1 synthesis was inhibited by replication stress caused by aphidicolin, preventing any replication past CFS. Importantly, POLH & POLK were still proficient in rescuing this stalled POLD1 synthesis. POLD1 stalling at CFSs allows for free exchange with specialized polymerase that is not driven by PCNA. PMID: 28605669
7. To our knowledge, the four Valencian families included in the present study are the only families where the POLD1 Leu474Pro mutation has been found. PMID: 28306219
8. We demonstrated an association between six previously published single nucleotide polymorphisms (rs15869 [ BRCA2], rs1805389 [ LIG4], rs8079544 [ TP53], rs25489 [ XRCC1], rs1673041 [ POLD1], and rs11615 [ ERCC1]) and subsequent CNS tumors in survivors of childhood cancer treated by radiation therapy. PMID: 28976792
9. The proofreading activity of DNA polymerase delta plays a role in shunting DNA mismatch repair to an EXO1-dependent excision pathway as opposed to directly participating in gap formation via its 3'-5' exonuclease activity. PMID: 28934474
10. Frameshift mutation in POLD1 gene is associated with mismatch repair-deficiency and Lynch syndrome. PMID: 28218421
11. the pathogenic role of the POLD1-R689W mutation in the development of the human tumor and emphasize the need to experimentally determine the significance of Poldelta variants present in sporadic tumors. PMID: 28368425
12. Our work highlights that mutations in different POLD1 domains can lead to phenotypic variability, ranging from dominantly inherited cancer predisposition syndromes, to mild MDPL phenotypes PMID: 28521875
13. Germline or somatic variants in the POLE/POLD1 were identified in unresolved suspected Lynch syndrome cancers with mismatch repair defect. PMID: 26648449
14. WRN or the Bloom syndrome helicase (BLM) stimulates DNA polymerase delta progression across telomeric G-rich repeats, only WRN promotes sequential strand displacement synthesis and FEN1 cleavage. PMID: 27849570
15. study of complete exonuclease domains of POLE and POLD1 in 529 families characterized by presence of familial or early-onset mismatch repair proficient colorectal cancer, and/or APC-negative and MUTYH-negative polyposis; results widen the phenotypic spectrum of the POLE/POLD1-associated syndrome and identify novel pathogenic variants PMID: 26133394
16. POLD1 is a central mediator of DNA replication and repair, and it is implied in cancer and other pathologies. (Review) PMID: 27320729
17. Inactivating POLD1 mutations are associated with colorectal cancer. PMID: 26755646
18. Mutations in POLE and POLD1 in south east Asia women with grade 3 endometrioid endometrial carcinomas are associated with improved recurrence free survival. PMID: 26748215
19. POLD1 germline mutations can result in a variably expressed and probably underdiagnosed segmental progeroid syndrome. PMID: 26172944
20. On the sequence, Escherichia coli oriC plasmid DNA, it was found hPold replicates DNA across the CCG repeats but hPole stalls at the CCG repeats even if the secondary structure is eliminated by a single stranded binding protein. PMID: 26271349
21. None of the 1188 patients carried the POLD1 p.(Ser478Asn) variant. POLE germline variant carriers are also associated with a microsatellite instable colorectal cancer PMID: 25370038
22. POLD1 plays important role in the regulation of cell cycle progression and DNA damage repair PMID: 26087769
23. analysis of phenotype of variants of the essential replicative polymerase-delta carrying missense mutations in its active site PMID: 25241845
24. POLE and POLD1 mutations explain a fraction of familial CRC and polyposis. Sequencing the proofreading domains of POLE and POLD1 should be considered in routine genetic diagnostics. PMID: 24501277
25. Germline mutations in the proofreading domains of 2 DNA polymerases (POLE and POLD1) have been associated with a dominantly inherited, highly penetrant syndrome of oligo adenomatous polyposis and early-age-of-diagnosis colorectal and endometrial cancer. PMID: 24509466
26. POLE and POLD1 mutations are associated with endometrial cancer. PMID: 23528559
27. a single-codon deletion in POLD1 affecting the polymerase active site causes a markedly different phenotype that includes lipodystrophy. PMID: 23770608
28. Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers. PMID: 23447401
29. the down-regulations of DNA pol delta1 are age-related and have little bearing on diseases and nutritures. DNA pol delta1 has great potential for a new biomarker of aging. PMID: 22915169
30. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. PMID: 23263490
31. the human lagging strand DNA polymerase delta holoenzyme is distributive PMID: 22942285
32. reducing expression of individual PRMT7 target DNA repair genes showed that only the catalytic subunit of DNA polymerase, POLD1, was able to resensitize PRMT7 knock-down cells to DNA-damaging agents. PMID: 22761421
33. Pol switches at replication-blocking lesions occur by the exchange of the Pol delta and Pol zeta catalytic subunits on a preassembled complex of accessory proteins retained on DNA during translesion DNA synthesis. PMID: 22465957
34. Coronavirus nsp13 and DNA polymerase delta induced DNA replication stress in IBV-infected cells. PMID: 21918226
35. POLD1 gene mutations are not responsible for the elevated HPRT mutation rates in a colon cancer cell line PMID: 14767555
36. ubiquitin and ubiquitin-like proteins modify the p66 and p12 subunits of DNA polymerase delta PMID: 16934752
37. Results suggest that the CDE/CHR-like sequence is an active functional element in the POLD1 promoter, which is important for the cell cycle regulation of the POLD1 gene. PMID: 19557333
顯示更多

收起更多
相關疾病：

Colorectal cancer 10 (CRCS10); Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome (MDPL)
亞細胞定位：

Nucleus.
蛋白家族：

DNA polymerase type-B family
組織特異性：

Widely expressed, with high levels of expression in heart and lung.
數據庫鏈接：

HGNC: 9175

OMIM: 174761

KEGG: hsa:5424

STRING: 9606.ENSP00000406046

UniGene: Hs.279413

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human